H.C. Wainwright analyst Patrick Trucchio lowered the firm’s price target on uniQure to $25 from $30 and keeps a Buy rating on the shares. While the company’s pipeline is on track, the price target cut reflects expectations regarding uniQure collaboration partner CSL Behring’s launch of Hemgenix, a gene therapy for hemophilia B, the analyst tells investors in a research note. The launch has been slower than the firm expected.
Elevate Your Investing Strategy:
- Take advantage of TipRanks Premium at 55% off! Unlock powerful investing tools, advanced data, and expert analyst insights to help you invest with confidence.
Published first on TheFly – the ultimate source for real-time, market-moving breaking financial news. Try Now>>
See the top stocks recommended by analysts >>
Read More on QURE:
- Snowflake downgraded and upgraded: Wall Street’s top analyst calls
- Goldman downgrades uniQure on uncertain path in Huntington’s
- uniQure downgraded to Neutral from Buy at Goldman Sachs
- A New Cause for Concern: uniQure N.V. Adds a New Innovation / R&D Risk
- uniQure reports FY23 EPS ($6.47), consensus ($6.31)